Han et al. recently conducted a retrospective study of PD-1-blocking antibodies (pembrolizumab or nivolumab) plus autologous CIK cells to evaluate the safety, efficacy, and impact of this treatment on immune function in patients with advanced NSCLC [14]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.